Keyphrases
Parkinson's Disease
100%
Leucine-rich Repeat Kinase 2 (LRRK2)
89%
Rab10
32%
Phosphorylation
26%
Human Peripheral Blood
19%
Peripheral Blood Neutrophils
19%
Tagless
19%
Clinical Samples
19%
Lysosome
19%
R1441C
14%
Mutation Carriers
14%
Patient Stratification
13%
VPS35
13%
Penetrance
12%
Kinase Activity
11%
Targeted Mass Spectrometry
11%
Parkinson
10%
Multiplexing
10%
Kinase Cascade
10%
Vesicle Trafficking Pathways
9%
Sortilin-related Receptor
9%
Lipoprotein Receptor-related Protein
9%
Parkinson's Disease Dementia
9%
Mitochondrial DNA Damage
9%
Accurate Mass Spectrometry
9%
Neutrophil Isolation
9%
Intracellular Vesicles
9%
Deep Phenotyping
9%
Receptor 1
9%
Penetrant
9%
Non-neuronal
9%
Molecular Mechanism
9%
Lewy Bodies
9%
Dementia with Lewy Bodies
9%
Microtubule Binding
9%
Bisphosphonates
9%
G2019S mutation
9%
Phosphorylation Stoichiometry
9%
Orally Bioavailable
9%
Blood-based
9%
Phospholipids
9%
Brain Cells
9%
Degrader
9%
Genetic Testing
9%
Blood-brain Barrier
9%
Proteolysis Targeting chimera (PROTAC)
9%
Immunoaffinity Enrichment
9%
Molecular Profiling
9%
Inflammation
9%
Crohn's Disease
9%
Interleukin-4 (IL-4)
9%
Disease-associated
9%
Protein Kinase 2
9%
Leucine-rich Repeat Protein
9%
Idiopathic Parkinson's Disease
8%
Pathogenic Variants
7%
Parkinson Patients
6%
Clinical Trials
6%
Blood Samples
5%
Protein Phosphorylation
5%
Neutrophils
5%
Lysosomal Storage Disease
5%
Co-immunoprecipitation (co-IP)
5%
Biochemistry, Genetics and Molecular Biology
Kinase
83%
Phosphotransferase
83%
Leucine-Rich Repeat
78%
LRRK2
29%
Mass Spectrometry
19%
Lysosome
19%
VPS35
16%
Penetrance
13%
Genetics
12%
Protein Kinases
10%
Protein Phosphorylation
10%
Stoichiometry
9%
DNA Damage
9%
Blood Brain Barrier
9%
Lipoprotein Receptor-Related Protein
9%
Clinical Research
9%
Ubiquitination
9%
Genetic Screening
9%
Phospholipid
9%
Mitochondrial DNA
9%
Proteolysis
9%
Antibody Affinity
9%
Interleukin 4
9%
Clinical Trial
7%
Genetic Test
6%
Immunoprecipitation
5%